C-erb-B2 (HER2/neu) expression in synovial sarcoma of the head and neck

Olsen, Randall J.; Lydiatt, William M.; Koepsell, Scott A.; Lydiatt, Daniel D.; Johansson, Sonny L.; Naumann, Sabine; Bridge, Julia A.; Neff, James R.; Hinrichs, Steven H.; Tarantolo, Stefano

doi:10.1002/hed.20267

Cited by 39 publications

(19 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Approximately 50% of their patients died of synovial sarcoma. These data are comparable with other reported series where the reported survival rates are typically between 40 and 60% [1,[3][4][5][6][7][8][9][10][11][12][13].…”

Section: Expert Commentarysupporting

confidence: 81%

“…Other series also reported the importance of postoperative radiotherapy. Typically, the postoperative radiation dose ranges from 60 to 66 Gy [3][4][5][6][7][8][9][10][11][12][13]. Conversely, the value of chemotherapy added as an adjuvant treatment modality is questionable.…”

Section: Expert Commentarymentioning

confidence: 99%

“…The disease is more common in men than women with a 3:2 ratio [1][2][3][4][5][6][7][8][9][10][11][12][13]. The histology of sarcomas is complex and immunohistochemical analysis is often required to differentiate one subtype from another.…”

Section: Expert Commentarymentioning

confidence: 99%

See 2 more Smart Citations

Treatment outcomes for patients with synovial sarcoma of the head and neck

Lee¹,

Shin²

2008

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

Evaluation of: Harb WJ, Luna MA, Patel SR, Ballo MT, Roberts DB, Sturgis EM. Survival in patients with synovial sarcoma of the head and neck: association with tumor location, size, and extension. Head Neck 29, 731-740 (2007). Synovial sarcoma of the head and neck occurs most commonly in males in their third decade of life. Synovial sarcoma of the head is rare, accounting for less than 10% of all head and neck sarcomas. Due to its rarity, there are very few publications on the treatment approach for these tumors. However, it is uniformly accepted that all head and neck synovial sarcomas should undergo complete surgical resection followed by postoperative radiation therapy in those at high risk for locoregional recurrence. In terms of chemotherapy, there are also emerging data on its effectiveness in the treatment of synovial sarcoma of the head and neck. The paper under evaluation reports a single institution's 36-year experience on the treatment of synovial sarcoma of the head and neck. This paper highlights the importance of a multidisciplinary approach in the treatment of this disease.

show abstract

Section: Expert Commentarysupporting

confidence: 81%

Section: Expert Commentarymentioning

confidence: 99%

See 1 more Smart Citation

Treatment outcomes for patients with synovial sarcoma of the head and neck

Lee¹,

Shin²

2008

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

show abstract

“…With β-C in the cell membrane and cytoplasm, the sarcoma cell appears as of epithelioid phenotype [101][102][103]108]. Apoptotic frequency, human endothelial growth factor receptor (Her2)/neu (C-erb-B2) and insulin-like growth factor (IGF)-2 expression of SS cells has prognostic value [109][110][111][112].…”

Section: Molecular Pathology and Geneticsmentioning

confidence: 99%

Adult human sarcomas. I. Basic science

Sinkovics¹

2007

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

When connective tissue undergoes malignant transformation, glioblastomas and sarcomas arise. However, the ancient biochemical mechanisms, which are now operational in sarcomas distorted by mutations and gene fusions in misaligned chromosomes, were originally acquired by those cells that emerged during the Cambrian explosion. Preserved throughout evolution up to the genus Homo, these mechanisms dictate the apoptosis- and senescence-resistant immortality of malignant cells. A 'retroviral paradox' distinguishes human sarcomas from those of the animal world. In contrast to the retrovirally induced sarcomatous transformation of animal (avian, murine, feline and simian) cells, human sarcomas have so far failed to yield a causative retroviral isolate. However, the proto-oncogenes/oncogenes transduced from their host cells by retroviruses of animals are the same that are active in human sarcomas. Since the encoded oncoproteins arise after birth, they are recognized frequently by the immune system of the host. Immune lymphocytes that kill autologous sarcoma cells in vitro commonly fail to do so in vivo. Sarcoma vaccines generate immune T- and natural killer cell reactions; even when vaccinated patients do not show a clinical response, their tumors become more sensitive to chemotherapy. The aim of this review is to lay a solid molecular biological foundation for the conclusion that targeting the sarcoma oncogenes will result in regression of the disease.

show abstract

“…plette Resektion manchmal nicht möglich war [20,21]. Des Weiteren wurde die Rolle des EGFR (endothelial growth factor receptor) und des Her-2/neu (human epithelial growth factor receptor 2) in der Karzinogenese des Synovialsarkoms untersucht [22,23]. Diese Untersuchungen geben Hinweise auf einen therapeutischen Ansatz mit monoklonalen anti-EGFR-Antikörpern.…”

unclassified

Spindelzellige Weichgewebstumoren des Para- u. Retropharyngealraums: 5 Patienten, Literaturübersicht

et al. 2015

View full text Add to dashboard Cite

Since malignant mesenchymal tumors of the PPR are unusual and also not have the typical behavior of metastatic epithelial neoplasms or malignant lymphoma, the diagnosis may be delayed. It is important to think in atypical lesions in PPR of the possibility of a soft tissue tumor and to arrange the necessary diagnostic steps. The imaging of choice of the PPR is the MRI, a staging adapted to the entity is necessary. The histological differentiation by immunohistochemistry and molecular genetics is complex, but is a vital to determine the optimal therapy. Diagnosis and treatment should take place in a specialized center.

show abstract

C-erb-B2 (HER2/neu) expression in synovial sarcoma of the head and neck

Cited by 39 publications

References 43 publications

Treatment outcomes for patients with synovial sarcoma of the head and neck

Treatment outcomes for patients with synovial sarcoma of the head and neck

Adult human sarcomas. I. Basic science

Spindelzellige Weichgewebstumoren des Para- u. Retropharyngealraums: 5 Patienten, Literaturübersicht

Contact Info

Product

Resources

About